.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
LEADER randomized more than 9,000 patients with type 2 diabetes and high cardiovascular risk to liraglutide or placebo. Liraglutide significantly reduced the primary composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke and also reduced all-cause mortality. These findings were among the key studies that moved GLP-1 receptor agonists into the cardiovascular-risk conversation. For internal-medicine practice, the significance is that therapy selection can be driven by organ protection as well as glucose lowering. Patients with established cardiovascular disease or multiple risk factors may therefore warrant consideration of agents with proven cardiovascular benefit. Clinicians still need to address weight, blood pressure, lipids, smoking and kidney disease, because a single medicine does not replace comprehensive risk-factor management. The trial also provides a useful framework for explaining why modern diabetes care has shifted from a glucose-centric model to a broader cardiometabolic model.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
LEADER randomized more than 9,000 patients with type 2 diabetes and high cardiovascular risk to liraglutide or placebo. Liraglutide significantly reduced the primary composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke and also reduced all-cause mortality. These findings were among the key studies that moved GLP-1 receptor agonists into the cardiovascular-risk conversation. For internal-medicine practice, the significance is that therapy selection can be driven by organ protection as well as glucose lowering. Patients with established cardiovascular disease or multiple risk factors may therefore warrant consideration of agents with proven cardiovascular benefit. Clinicians still need to address weight, blood pressure, lipids, smoking and kidney disease, because a single medicine does not replace comprehensive risk-factor management. The trial also provides a useful framework for explaining why modern diabetes care has shifted from a glucose-centric model to a broader cardiometabolic model.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
